How to identify poison ivy, poison oak and poison sumac. What you should know to prevent a rash.

Chemo rash is one of the most common side effects of cancer treatment. These rashes usually aren’t serious, but they can cause pain, itching, and other uncomfortable symptoms.

Kura Oncology initiates KOMET-015 trial studying ziftomenib plus imatinib for advanced GIST post-imatinib failure.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Imatinib potentially affects immune cells directly, and several cases showed improvement in psoriasis after the introduction of imatinib. 2, 3 By contrast, exacerbation of psoriasis or do novo ...

The most common treatment-related adverse effects (TRAEs) reported with imatinib include edema, nausea/vomiting, muscle cramps, musculoskeletal pain, diarrhea, and rash. Edema primarily occurred ...

Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially ...

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

The short-term toxicities of imatinib include superficial edema, muscle cramps, nausea, musculoskeletal pain, diarrhea, rash, fatigue, headache, abdominal pain, and joint pain in more than 10% of the ...

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial ...

Continuous Gleevec treatment in GIST patients significantly prolongs progression-free survival and delays resistance compared to treatment interruption. Median progression-free survival was 6.1 months ...

Imatinib remains the first-line standard for advanced GIST with imatinib-sensitive mutations. Whether treatment interruption affects resistance to imatinib or survival remains unclear, Blay and ...